
First Quarter 2025
First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Thursday April 24, 2025
Press Releases
June 23, 2025
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
June 20, 2025
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
June 17, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue
Upcoming Events
19Jun
2025
JPM European Healthcare Forum
08:00 - 15:00 GMT (London)
Conferences
31Jul
2025
Second Quarter 2025
Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation will be followed by a Q&A session.
15:00 - 16:30 CET (9:00am – 10:30am EDT)
Quarterly results

30th Consecutive Year of Dividend Increase

Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00